Report Detail

Pharma & Healthcare Cluster Headache Syndrome (Cluster Headache) - Pipeline Review, H2 2019

  • RnM3727954
  • |
  • 05 September, 2019
  • |
  • Global
  • |
  • 58 Pages
  • |
  • Global Markets Direct
  • |
  • Pharma & Healthcare

Cluster Headache Syndrome (Cluster Headache) - Pipeline Review, H2 2019

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cluster Headache Syndrome - Pipeline Review, H2 2019, provides an overview of the Cluster Headache Syndrome (Central Nervous System) pipeline landscape.

Cluster headache is pain that occurs along one side of the head. It is frequently occurs around, behind, or above the eye. Symptoms include burning, sharp, steady pain, red eye, runny nose, excessive tearing and flushed face. Risk factors include age and gender. Treatment includes anti-inflammatory (steroid) medicines and triptans.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cluster Headache Syndrome - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Cluster Headache Syndrome (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Cluster Headache Syndrome (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Cluster Headache Syndrome (Cluster Headache) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 1, 1, 1, 1 and 2 respectively. Similarly, the Universities portfolio in Phase I stages comprises 1 molecules, respectively.

Cluster Headache Syndrome (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Cluster Headache Syndrome (Central Nervous System).
- The pipeline guide reviews pipeline therapeutics for Cluster Headache Syndrome (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Cluster Headache Syndrome (Central Nervous System) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Cluster Headache Syndrome (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Cluster Headache Syndrome (Central Nervous System)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Cluster Headache Syndrome (Central Nervous System).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Cluster Headache Syndrome (Central Nervous System) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Table of Contents

    List of Tables

      List of Figures

        Introduction

          Global Markets Direct Report Coverage

            Cluster Headache Syndrome (Cluster Headache) - Overview

              Cluster Headache Syndrome (Cluster Headache) - Therapeutics Development

                Pipeline Overview

                  Pipeline by Companies

                    Pipeline by Universities/Institutes

                      Products under Development by Companies

                        Products under Development by Universities/Institutes

                          Cluster Headache Syndrome (Cluster Headache) - Therapeutics Assessment

                            Assessment by Target

                              Assessment by Mechanism of Action

                                Assessment by Route of Administration

                                  Assessment by Molecule Type

                                    Cluster Headache Syndrome (Cluster Headache) - Companies Involved in Therapeutics Development

                                      Clexio Biosciences Ltd

                                        Crossject SA

                                          Eli Lilly and Co

                                            TrioxBio Inc

                                              Zosano Pharma Corp

                                                Cluster Headache Syndrome (Cluster Headache) - Drug Profiles

                                                  CLE-500 - Drug Profile

                                                    Product Description

                                                      Mechanism Of Action

                                                        R&D Progress

                                                          galcanezumab - Drug Profile

                                                            Product Description

                                                              Mechanism Of Action

                                                                R&D Progress

                                                                  MTR-108 - Drug Profile

                                                                    Product Description

                                                                      Mechanism Of Action

                                                                        R&D Progress

                                                                          psilocybin - Drug Profile

                                                                            Product Description

                                                                              Mechanism Of Action

                                                                                R&D Progress

                                                                                  sumatriptan - Drug Profile

                                                                                    Product Description

                                                                                      Mechanism Of Action

                                                                                        R&D Progress

                                                                                          zolmitriptan - Drug Profile

                                                                                            Product Description

                                                                                              Mechanism Of Action

                                                                                                R&D Progress

                                                                                                  zucapsaicin - Drug Profile

                                                                                                    Product Description

                                                                                                      Mechanism Of Action

                                                                                                        R&D Progress

                                                                                                          Cluster Headache Syndrome (Cluster Headache) - Dormant Projects

                                                                                                            Cluster Headache Syndrome (Cluster Headache) - Discontinued Products

                                                                                                              Cluster Headache Syndrome (Cluster Headache) - Product Development Milestones

                                                                                                                Featured News & Press Releases

                                                                                                                  Aug 14, 2019: Zosano Pharma files IND to Initiate a phase 2/3 Clinical Study in Cluster Headache

                                                                                                                    Jul 11, 2019: New England Journal of Medicine publishes positive phase 3 data for Emgality (galcanezumab-gnlm) in episodic cluster headache

                                                                                                                      Jun 05, 2019: FDA approves first drug for episodic cluster headaches

                                                                                                                        May 02, 2019: Lilly to present new data at AAN 2019 on Emgality (galcanezumab-gnlm) reinforcing breadth of headache disorders portfolio

                                                                                                                          Mar 05, 2019: Lilly receives FDA Priority Review Designation for Emgality (galcanezumab-gnlm) Injection for the preventive treatment of Episodic Cluster Headache in Adults

                                                                                                                            Nov 14, 2018: Emgality receives Breakthrough Therapy Designation for prevention of Episodic Cluster Headache

                                                                                                                              May 15, 2018: Lilly's Galcanezumab Meets Primary Endpoint in Phase 3 Study Evaluating Galcanezumab for the Prevention of Episodic Cluster Headache

                                                                                                                                Sep 06, 2017: Lilly To Present New Data For Galcanezumab At The 18th Congress Of The International Headache Society

                                                                                                                                  Appendix

                                                                                                                                    Methodology

                                                                                                                                      Coverage

                                                                                                                                        Secondary Research

                                                                                                                                          Primary Research

                                                                                                                                            Expert Panel Validation

                                                                                                                                              Contact Us

                                                                                                                                                Disclaimer

                                                                                                                                                Summary:
                                                                                                                                                Get latest Market Research Reports on Cluster Headache Syndrome (Cluster Headache). Industry analysis & Market Report on Cluster Headache Syndrome (Cluster Headache) is a syndicated market report, published as Cluster Headache Syndrome (Cluster Headache) - Pipeline Review, H2 2019. It is complete Research Study and Industry Analysis of Cluster Headache Syndrome (Cluster Headache) market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

                                                                                                                                                Last updated on

                                                                                                                                                REPORT YOU MIGHT BE INTERESTED

                                                                                                                                                Purchase this Report

                                                                                                                                                $2,000.00
                                                                                                                                                $4,000.00
                                                                                                                                                $6,000.00
                                                                                                                                                1,600.00
                                                                                                                                                3,200.00
                                                                                                                                                4,800.00
                                                                                                                                                1,868.00
                                                                                                                                                3,736.00
                                                                                                                                                5,604.00
                                                                                                                                                314,660.00
                                                                                                                                                629,320.00
                                                                                                                                                943,980.00
                                                                                                                                                166,780.00
                                                                                                                                                333,560.00
                                                                                                                                                500,340.00
                                                                                                                                                Credit card Logo

                                                                                                                                                Related Reports


                                                                                                                                                Reason to Buy

                                                                                                                                                Request for Sample of this report